Metformin-glibenclamide versus metformin plus rosiglitazone in patients with type 2 diabetes inadequately controlled on metformin monotherapy.
Metformin-glibenclamide versus metformin plus rosiglitazone in patients with type 2 diabetes, unrecommended metformin monotherapy